We see you are visiting from an Internet Explorer browser. Due to the deprecation of Internet Explorer and for security reasons, the PSG site is not supported in Internet Explorer. For the best experience, please use an alternate browser.

Loopback connects Health Systems and Life Sciences through analytics and data-enabled services.

Psg portfolio loopbackanalytics background 1

Founded in 2009, Loopback Analytics is a leading provider of data analytics and insights that simplify understanding, access and innovation for patients requiring specialty care.

The platform enables:

  • Health Systems to help identify, understand and engage their most complex specialty patients
  • Health System Clients to help secure specialty pharmacy payor and limited distribution drug access
  • Innovators across research and industry to help identify, understand and engage in nuanced patient and therapy journeys
  • Researchers to help identify and understand the markers and journey for rare diagnoses

Health system specialty and ambulatory pharmacy programs are positioned to help provide superior care for patients through their close relationship with prescribers and integrated care model, and the Loopback data platform helps support and enable these organizations to capitalize on growth opportunities and improve patient outcomes.

Healthcare and Life Science stakeholders use the Loopback clinical intelligence platform to identify and understand how patient cohorts that would otherwise be difficult to identify and quantify are treated in the real world.

Year Invested
2023
Location
Dallas, TX
Website
loopbackanalytics.com
"Our partnership with PSG is a game-changer. Their financial support is enabling us to expand our capabilities for client service and new product development. PSG also brings knowledge, expertise and relationships that have helped us expand our vision of what is possible and have helped position us for success in capitalizing on the opportunity in front of us."
— Neil Smiley, CEO at Loopback

This statement is provided by an executive of a portfolio company of a PSG fund. PSG has not provided cash or other compensation in exchange for receiving this statement. Any discretion PSG exercises in the determination of the compensation of its portfolio company executives, or other benefits provided to such executives, is not influenced by whether such executive has provided a favorable statement. Nevertheless, the fact that any statements have been provided by individuals whose compensation PSG exercises a certain level of control over, or who may receive certain benefits from PSG, may incentivize such individuals to provide favorable evaluations of their experiences working with PSG. The executive is not an investor in strategies sponsored by PSG.

Next Company
Psg portfolio lumaverse logo

Lumaverse Technologies provides constituent management and engagement software for nonprofits and education.